BioSante Pharmaceuticals To Present at Rodman & Renshaw Techvest Global Healthcare Conference
02 May 2005 - 10:00PM
Business Wire
BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M.
Simes, president and chief executive officer, will present a
corporate overview at the Rodman & Renshaw Techvest 2nd Annual
Global Healthcare Conference. The presentation will take place on
May 5, 2005 at 7:00 a.m. EDT (1:00 p.m. local Paris time) at the
Intercontinental Hotel in Paris, France. The Rodman & Renshaw
Techvest 2nd Annual Global Healthcare Conference is expected to
include more than 160 presenting companies and more than 700
attendees. A live audio webcast of the presentation can be accessed
on the internet by visiting http://www.wsw.com/webcast/rrshq5/bpa/.
Beginning May 5, a replay of the presentation will be available at
the same link for 90 days. For more information on the Rodman &
Renshaw Conference, visit www.rodmanandrenshaw.com/eu05conference.
About BioSante Pharmaceuticals, Inc. BioSante is developing a
pipeline of hormone therapy products to treat both men and women.
These hormone therapy products are gel formulations for transdermal
administration that deliver bioidentical estradiol and
testosterone. BioSante's lead products include Bio-E-Gel(TM)
(bioidentical estradiol gel) for the treatment of women with
menopausal symptoms, and LibiGel(TM) (bioidentical testosterone
gel) for the treatment of female sexual dysfunction (FSD). The
current market in the U.S. for estrogen and testosterone products
is approximately $2.5 billion. The company also is developing its
calcium phosphate nanotechnology (CAP) for novel vaccines,
including biodefense vaccines for toxins such as anthrax and ricin,
and drug delivery systems. Additional information is available
online at www.biosantepharma.com. This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The statements regarding
BioSante contained in this press release that are not historical in
nature, particularly those that utilize terminology such as "may,"
"will," "should," "likely," "expects," "anticipates," "estimates,"
"believes" or "plans," or comparable terminology, are
forward-looking statements. Forward-looking statements are based on
current expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements. Important
factors known to BioSante that cause actual results to differ
materially from those expressed in such forward-looking statements
are the difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance, and
other factors identified and discussed from time to time in
BioSante's filings with the Securities and Exchange Commission,
including those factors discussed on pages 19 to 31 of BioSante's
Form 10-KSB, which discussion also is incorporated herein by
reference.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
More BioSante Pharmaceuticals, Inc. News Articles